| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.085 | 0.009 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.096 | 0.009 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.095 | 0.009 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.15 | 0.009 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.009 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.17 | 0.01 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.15 | 0.01 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |